Qualigen Therapeutics, Inc.
QLGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.19 | 1.16 | 3.72 |
| FCF Yield | -415.66% | -7.39% | -5.48% | -0.95% |
| EV / EBITDA | -0.07 | -12.42 | -17.77 | -69.54 |
| Quality | ||||
| ROIC | -215.29% | 1,404.94% | -162.11% | -123.65% |
| Gross Margin | 0.00% | -0.09% | 13.66% | 23.37% |
| Cash Conversion Ratio | 1.00 | 0.83 | 1.15 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -2.72% | 4.99% | 0.57% |
| Free Cash Flow Growth | 38.59% | 24.05% | 8.78% | -49.24% |
| Safety | ||||
| Net Debt / EBITDA | 0.22 | -0.08 | 0.10 | 0.71 |
| Interest Coverage | -6.34 | -7.41 | -521.63 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 2.71 | 4.10 |
| Cash Conversion Cycle | 0.00 | -155.76 | 121.45 | 67.38 |